Try
Immunocore Holdings plc
IMCRUnited States
16 filed reports · 609 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
16 reports · Dec 2020 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 52 interim figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 8 | 1,415 | Mar 2024 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 3 | 1,377 | Dec 2023 to Dec 2025 |
| Annual · 20-FSEC EDGAR | 3 | 1,550 | Dec 2020 to Dec 2022 |
| Interim · 6-KSEC EDGAR | 1 | 216 | Jun 2023 |
| Interim · 6-K/ASEC EDGAR | 1 | 158 | Sep 2022 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 298 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 179 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 25, 2026 | 702 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 211 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 127 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 7, 2025 | 141 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 26, 2025 | 311 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 6, 2024 | 164 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 8, 2024 | 131 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 8, 2024 | 164 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 28, 2024 | 364 | Open |
| FY2023 Q2 | 6-K | Jun 30, 2023 | Aug 10, 2023 | 216 | Open |
Financial data
609 concepts · 4,716 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial582 concepts · 4,332 facts · Dec 2018 to Jul 2026
- Revenue30 · Dec 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents23 · Dec 2020 to Jun 2026
- Stockholders equity (US GAAP)23 · Dec 2020 to Jun 2026
- Share based compensation arrangement by share based payment award options outstanding number20 · Dec 2020 to Jun 2026
- Share based compensation arrangement by share based payment award options outstanding weighted average exercise price20 · Dec 2020 to Jun 2026
- Adjustments to additional paid in capital share based compensation stock options requisite service period recognition19 · Dec 2021 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect19 · Dec 2021 to Jun 2026
- Comprehensive income net of tax19 · Dec 2021 to Jun 2026
- Cost of revenue (US GAAP)19 · Dec 2021 to Jun 2026
- Depreciation19 · Dec 2021 to Jun 2026
- Effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents19 · Dec 2021 to Jun 2026
- Foreign currency transaction gain loss before tax19 · Dec 2021 to Jun 2026
- Foreign currency transaction gain loss unrealized19 · Dec 2021 to Jun 2026
- Income taxes paid net19 · Dec 2021 to Jun 2026
- Income tax expense benefit19 · Dec 2021 to Jun 2026
- Increase decrease in accounts payable19 · Dec 2021 to Jun 2026
- Increase decrease in accounts receivable19 · Dec 2021 to Jun 2026
- Increase decrease in accrued liabilities19 · Dec 2021 to Jun 2026
- Increase decrease in operating lease liability19 · Dec 2021 to Jun 2026
- Increase decrease in other operating assets19 · Dec 2021 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets19 · Dec 2021 to Jun 2026
- Investment income interest19 · Dec 2021 to Jun 2026
- Net cash provided by used in financing activities19 · Dec 2021 to Jun 2026
- Net cash provided by used in investing activities19 · Dec 2021 to Jun 2026
Product9 concepts · 174 facts · Dec 2018 to Jun 2026
- Revenue115 · Dec 2018 to Jun 2026
- Eli Lilly23 · Dec 2019 to Jun 2023
- Revenue from performance obligations satisfied or partially satisfied in previous periods16 · Dec 2018 to Dec 2022
- Other revenue (IFRS)7 · Dec 2020 to Dec 2022
- Research and development expense (IFRS)6 · Dec 2019 to Dec 2021
- Percentage of entitys revenue3 · Dec 2021 to Dec 2022
- Cost of inventories recognised as expense during period2 · Dec 2022
- Adjustments for increase decrease in deferred income1 · Dec 2020
- GlaxoSmithKline1 · Dec 2020
Geography13 concepts · 140 facts · Dec 2018 to Dec 2025
- Revenue49 · Dec 2018 to Dec 2023
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest18 · Dec 2021 to Dec 2025
- Current income tax expense benefit16 · Dec 2021 to Dec 2025
- Deferred income tax expense benefit16 · Dec 2021 to Dec 2025
- Current tax expense income8 · Dec 2018 to Dec 2022
- Deferred tax expense income8 · Dec 2018 to Dec 2022
- United Kingdom7 · Dec 2018 to Dec 2023
- Applicable tax rate5 · Dec 2018 to Dec 2022
- United States5 · Dec 2018 to Dec 2022
- Income tax relating to availableforsale financial assets of other comprehensive income3 · Dec 2018 to Dec 2020
- Revenue from contracts with customers2 · Dec 2020 to Dec 2021
- Tax benefit arising from previously unrecognised tax loss tax credit or temporary difference of prior period used to reduce current tax expense2 · Dec 2021 to Sep 2022
- Income tax expense benefit1 · Mar 2024
Segment5 concepts · 70 facts · Dec 2022 to Jun 2026
- Cost of revenue (US GAAP)14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Research and development expense14 · Dec 2022 to Jun 2026
- Revenue14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
Segments
384 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service4 members · 103 facts
- Sale Of Therapies56 · Dec 2022 to Jun 2026
- Product28 · Dec 2021 to Sep 2024
- Collaboration Revenue16 · Dec 2022 to Dec 2025
- Pre Product3 · Dec 2021 to Dec 2023
Geographical areas8 members · 79 facts
- GB27 · Dec 2018 to Dec 2022
- US21 · Dec 2018 to Jun 2023
- XBC10 · Dec 2019 to Jun 2023
- Rest Of World9 · Dec 2020 to Jun 2023
- IE6 · Dec 2020 to Dec 2022
- Us2 · Sep 2021 to Sep 2022
- Xbc2 · Sep 2021 to Sep 2022
- Rest of world2 · Sep 2021 to Sep 2022
Products and services6 members · 71 facts
- Genentech27 · Dec 2018 to Jun 2023
- Eli Lilly19 · Dec 2018 to Jun 2023
- Glaxo Smith Kline19 · Dec 2018 to Dec 2022
- Med Immune4 · Dec 2018 to Dec 2020
- Inventory On Hand1 · Dec 2022
- KIMMTRAK1 · Dec 2022
Statement geographical6 members · 61 facts
- US17 · Dec 2021 to Dec 2025
- GB15 · Dec 2021 to Dec 2025
- Other Worldwide14 · Dec 2021 to Dec 2025
- IE9 · Dec 2023 to Dec 2025
- Europe3 · Dec 2021 to Dec 2023
- Rest Of World3 · Dec 2021 to Dec 2023
Statement business segments1 member · 56 facts
- Reportable56 · Dec 2022 to Jun 2026
Subsegments1 member · 14 facts
- External RD14 · Dec 2022 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 6, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.